Ray Blanco is the editor of Technology Profits Confidential as well as Breakthrough Technology Alert, Ray Blanco’s FDA Trader, Penny Pot Profits and Technology Profits Daily. Ray has been with Seven Figure Publishing for nine years. In 2018, his closed positions in Technology Profits Confidential averaged over 100% gains.
Android counts with an army of 450,000 developers. It is the applications that count the most for end users. An operating system can be easy to use, secure and efficient, but it is useless in the consumer market without a large variety of desirable apps.
Seattle Genetics'lead drug candidate, brentuximab vedotin, won coveted priority review status from the FDA and NVE Corp. reported a record fiscal year.
Advisory Panel to Deliver Recommendation on Vertex and Seattle Genetics Expands Collaborative Targets
I'd like to provide a couple of updates on some of our biotechnology companies.The hepatitis C drug developed by Vertex Pharmaceuticals is up for an FDA advisory panel meeting next week. And... Seattle Genetics has realized a second antibody drug conjugate (ADC) collaboration with fellow biotech innovator Genmab.
American Superconductor shares plummeted this morning when an after-hours press release on Tuesday revealed that its largest Chinese customer, Sinovel, is refusing to accept contracted shipments of wind turbine components, and refusing to pay for shipments made last year.
There are emerging technologies in development sitting at the crossroads between traditional technology and biotechnology. With a greater ability to tailor solutions using the basic building blocks of matter, a great convergence is taking place. As these innovations become commercialized, they will present new investment opportunities.
Japan is reeling from a major natural disaster that struck last Friday. Over the past week, the news media and blogs have been full of images and videos showing massive damage sustained by towns in northern Japan. Let's take a look at the lastest information along with any effects on our portfolio...
Stem cells are simply too important for an investor to ignore. In biotechnology, no field is more transformational or disruptive than stem cell science. Stem cell therapies will yield profits that will be unmatched in investing history. There is no surer way to make transformational returns over the long run than investing in transformational technology.
I want to share some information posted earlier this month in a Cisco forecast, the Global Mobile Data Traffic Forecast Update, and how the expected fulfillment of the forecast impacts our mobile technology picks. Although I recommend reading the entire white paper, I'd like to highlight some of the projections made by Cisco's analysts. They are, to say the least, astonishing.